What is boldine and what plant does it come from?

Boldine is an aporphine alkaloid (CAS #476-70-0; MW 327.4 g/mol) and the principal bioactive compound in the Chilean boldo tree (Peumus boldus), extracted primarily from its bark and aromatic leaves. It constitutes 12–19% of the total alkaloid fraction in boldo leaves, which contain 0.4–0.5% alkaloids by dry weight, yielding up to 6% pure boldine under optimized extraction conditions. It is one of the most concentrated single aporphine alkaloids found in any plant source.

Is boldine safe to take as a supplement?

Genotoxicity studies show boldine produced no chromosome aberrations in human lymphocytes at up to 40 μg/mL or in mouse bone marrow at oral doses up to 900 mg/kg, indicating a favorable safety profile for mutagenic risk. No serious adverse effects have been documented in preclinical studies, and its rapid metabolism (half-life ~30 min) minimizes accumulation risk. However, no human clinical trials have established safe supplemental dose ranges, and individuals taking dopaminergic or cholinergic medications should exercise caution due to boldine's receptor interactions.

What is the effective dose of boldine in humans?

No established human supplemental dose exists for boldine because no human clinical trials have been completed. Rodent studies use oral doses of 20–75 mg/kg, achieving peak plasma concentrations of approximately 7 μM at 25 mg/kg and hepatic concentrations of ~72 nmol/g at 50 mg/kg. Direct extrapolation to humans is complicated by boldine's low oral bioavailability (below 20%) from extensive hepatic first-pass metabolism and a short plasma half-life of approximately 30 minutes.

Does boldine have anti-inflammatory properties?

Yes, in preclinical models boldine reduces key inflammatory mediators including TNF-α, inducible nitric oxide synthase (iNOS), and myeloperoxidase activity, suggesting multi-target suppression of the inflammatory cascade. It also blocks connexin 43 hemichannels at 50–100 μM in astrocytes, microglia, and mesangial cells, which limits paracrine spread of inflammatory signals in neural and renal tissues. All evidence is from cell culture and rodent studies; human anti-inflammatory efficacy has not been demonstrated in controlled trials.

How does boldine differ from taking boldo leaf tea or extract?

Isolated boldine is a single purified alkaloid (MW 327.4 g/mol), whereas boldo leaf tea or crude extract contains the full spectrum of at least 17 alkaloids plus volatile oils (including the potentially hepatotoxic ascaridole), flavonoids, and tannins. This means boldo leaf preparations carry additional phytochemical interactions and safety considerations—particularly ascaridole-associated hepatotoxicity risk—that do not apply to purified boldine. Commercial supplements standardized to boldine content occupy an intermediate position, reducing but not eliminating matrix variability compared to raw leaf preparations.

Does boldine interact with common medications?

Boldine may interact with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, potentially altering drug levels in the body. It can also potentiate the effects of anticoagulants and antiplatelet medications due to its antioxidant properties. Individuals taking prescription medications should consult a healthcare provider before adding boldine supplementation to avoid adverse interactions.

Is boldine safe during pregnancy and breastfeeding?

There is insufficient clinical data on boldine's safety during pregnancy and breastfeeding, and traditional boldo use has been contraindicated in these populations due to potential effects on uterine smooth muscle. Pregnant and nursing women should avoid boldine supplementation unless explicitly approved by their healthcare provider. The lack of adequate human studies makes it prudent to err on the side of caution during these critical periods.

What does clinical research show about boldine's antioxidant effectiveness compared to other antioxidants?

In vitro studies demonstrate that boldine's IC50 values of 5–15 μM for scavenging alkylperoxyl radicals are comparable to established antioxidants, with the added benefit of upregulating endogenous antioxidant enzymes like superoxide dismutase and glutathione peroxidase. However, most evidence is limited to laboratory and animal models, with limited human clinical trials confirming equivalent or superior antioxidant benefits to other supplemental antioxidants. More robust human studies are needed to establish boldine's practical antioxidant efficacy relative to vitamin C, vitamin E, or polyphenol-rich extracts.

Boldine

Boldine (CAS #476-70-0; MW 327.4 g/mol) is a dual-phenolic aporphine alkaloid that scavenges free radicals with an IC50 of 5–15 μM, modulates superoxide dismutase and glutathione systems, suppresses TNF-α and iNOS, and blocks connexin hemichannels at 50–100 μM. Preclinical data in rodent models demonstrate hepatoprotective effects at liver concentrations of 72–88 μM, endothelial-protective activity at 20 mg/kg oral dosing, and neuroprotective preservation of mitochondrial membrane potential in PC12 cells at 10–100 μM, though no human clinical trials have yet confirmed these outcomes.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Boldine is the principal aporphine alkaloid isolated from the Chilean boldo tree (Peumus boldus Molina), a dioecious evergreen native to the coastal ranges and Andean foothills of Chile and Peru, where it thrives in dry, rocky, Mediterranean-type climates. The alkaloid is concentrated primarily in the bark and aromatic leaves, which yield up to 6% boldine by dry weight, making boldo one of the richest natural sources of a single aporphine alkaloid known. Commercial extraction has historically centered in Chile, where boldo is a protected and culturally significant native species harvested from wild and semi-cultivated stands.

Historical & Cultural Context

The boldo tree has been used medicinally by the indigenous Mapuche people of Chile for centuries, with boldo leaves prescribed as a mild hypnotic, diuretic, digestive tonic, and remedy for liver and gallbladder complaints including cholelithiasis and hepatic congestion. European settlers in South America adopted boldo as a folk hepatic remedy in the 19th century, and by the late 1800s, boldo leaf preparations had entered European phytomedicine, with formal botanical description by Molina in 1782 firmly establishing it in colonial-era natural history. The isolation of boldine as the principal alkaloid fraction was achieved in the early 20th century, and it became one of the earliest South American alkaloids subjected to systematic phytochemical analysis, contributing to foundational work on the aporphine alkaloid class. Today boldo leaf is listed in the European Pharmacopoeia and recognized by Germany's Commission E as a traditional remedy for dyspeptic complaints and mild hepatobiliary dysfunction, representing one of the few Latin American medicinal plants with formal Western phytomedicine monograph status.

Health Benefits

- **Antioxidant Activity**: Boldine scavenges alkylperoxyl and other reactive oxygen species with an IC50 of 5–15 μM, attributed to its two phenolic hydroxyl groups, and concurrently upregulates endogenous antioxidant enzymes including superoxide dismutase and glutathione peroxidase while reducing malondialdehyde (MDA) levels in oxidative stress models.
- **Anti-Inflammatory Action**: At pharmacologically relevant concentrations, boldine reduces pro-inflammatory cytokines TNF-α and suppresses inducible nitric oxide synthase (iNOS) and myeloperoxidase activity, collectively attenuating the inflammatory cascade observed in rodent models of metabolic and vascular disease.
- **Hepatoprotection**: Oral administration of 50 mg/kg in rodents achieves hepatic boldine concentrations of approximately 72 nmol/g, associated with reduced hepatocyte apoptosis via downregulation of caspase-3 and BAX expression, suggesting a direct cytoprotective effect at the liver cell level.
- **Cardiovascular and Endothelial Protection**: At 20 mg/kg oral or intraperitoneal dosing for 7 days, boldine improved endothelial function in aortic preparations from spontaneously hypertensive rats (SHR) and streptozotocin-induced diabetic rats, partly through inhibition of angiotensin-converting enzyme (ACE-1) and reduction of oxidative vascular stress.
- **Neuroprotection**: Boldine at 10–100 μM protected PC12 neuronal cells by attenuating catecholamine-induced mitochondrial swelling and preventing loss of mitochondrial membrane potential; it also modulates dopamine D2 receptors and nicotinic acetylcholine receptors, suggesting relevance to dopaminergic and cholinergic neuropathology.
- **Connexin Hemichannel Blockade**: Boldine blocks connexin 43 hemichannels at 50–100 μM in rat mesangial cells, hippocampal slice preparations, astrocytes, and microglia, inhibiting ethidium bromide uptake and potentially limiting paracrine propagation of inflammatory and cytotoxic signals in neural and renal tissue.
- **Skin Brightening (Topical Derivative)**: The diacetyl derivative dicetyl boldine, marketed as Lumiskin™, is used in cosmetic formulations for its melanin-suppressing properties, representing a commercially developed application of boldine's chemical scaffold beyond internal supplementation.

How It Works

Boldine's antioxidant activity is primarily conferred by its two catechol-type phenolic hydroxyl groups, which donate hydrogen atoms to neutralize alkylperoxyl, superoxide, and peroxynitrite radicals at IC50 values of 5–15 μM, while simultaneously upregulating superoxide dismutase and glutathione redox systems and reducing lipid peroxidation marker MDA. At 50–100 μM, boldine selectively blocks connexin 43 hemichannels—large-conductance membrane pores on astrocytes, microglia, hippocampal neurons, and mesangial cells—preventing aberrant ATP and glutamate release and limiting neuroinflammatory signal propagation, as evidenced by inhibition of ethidium bromide dye uptake in multiple cell types. Boldine interacts with dopamine D2 receptors and nicotinic acetylcholine receptors as a partial modulator, inhibits acetylcholinesterase, and at 300 μM potentiates ryanodine receptor-mediated calcium release in muscle preparations, indicating broad receptor-level bioactivity. Anti-inflammatory effects converge on suppression of TNF-α transcription, iNOS-mediated nitric oxide overproduction, and myeloperoxidase-driven oxidative burst, while anti-apoptotic signaling involves downregulation of caspase-3 and BAX in hepatic and neuronal cell contexts.

Scientific Research

The totality of boldine research consists exclusively of in vitro cell culture experiments and in vivo rodent pharmacology studies; no published human clinical trials with defined sample sizes, randomization, or effect-size reporting have been identified as of 2024, placing the evidence base firmly in the preclinical tier. Key in vitro findings include connexin hemichannel inhibition demonstrated across at least four cell types (rat mesangial cells, hippocampal slices, astrocytes, microglia) at 50–100 μM, and PC12 neuroprotection at 10–100 μM against catecholamine-induced mitochondrial dysfunction. Animal pharmacokinetic studies in rats establish a peak plasma concentration of approximately 7 μM following 25 mg/kg oral dosing with a short half-life of ~30 minutes and hepatic first-pass metabolism limiting systemic bioavailability to below 20%, which substantially complicates extrapolation to human dosing regimens. Genotoxicity studies are an exception in providing reasonably robust safety data: boldine produced no chromosome aberrations in human lymphocytes at ≤40 μg/mL or in mouse bone marrow at oral doses up to 900 mg/kg, supporting a favorable mutagenic safety profile, though systemic efficacy in humans remains entirely unproven.

Clinical Summary

No human clinical trials of boldine as an isolated compound have been completed or reported in the peer-reviewed literature; all efficacy data derive from preclinical in vitro and rodent models, making definitive clinical conclusions impossible at this time. Animal studies have investigated oral and intraperitoneal doses of 20–75 mg/kg, with the most pharmacologically informative endothelial protection data coming from 7-day administration studies in SHR and diabetic rat aortic models, where improvements in vascular relaxation and oxidative markers were observed but not translated to human endpoints. The absence of pharmacodynamic human data, combined with the compound's low oral bioavailability (<20%) and rapid plasma clearance (half-life ~30 min), presents significant translational challenges that preclinical researchers have not yet systematically addressed in clinical study design. Confidence in boldine's therapeutic potential in humans must therefore be classified as speculative pending Phase I/II trials establishing safe human dose ranges, pharmacokinetics, and preliminary efficacy signals.

Nutritional Profile

Boldine as an isolated alkaloid compound has no conventional macronutrient or micronutrient profile; it is a single molecular entity (C19H21NO4; MW 327.4 g/mol) rather than a food matrix. Its physicochemical properties include a calculated logP of +1.7 (moderately lipophilic), pKa of approximately 9.7–10.8 for the tertiary amine nitrogen, and two free phenolic hydroxyl groups responsible for hydrogen-bonding capacity and antioxidant electron donation. In the source plant (Peumus boldus leaves), boldine represents 12–19% of a total alkaloid pool of 0.4–0.5% of dry leaf weight, yielding up to 6% pure boldine by optimized extraction; the leaves also contain volatile essential oils (ascaridole, p-cymene), flavonoids, and tannins that contribute to the whole-plant pharmacological profile but are absent in isolated boldine preparations. Bioavailability of orally ingested boldine is below 20% due to extensive hepatic first-pass metabolism, with the compound exhibiting high plasma protein binding and membrane partitioning behavior that limits free-fraction concentrations in systemic circulation.

Preparation & Dosage

- **Traditional Boldo Leaf Tea**: Aqueous infusion of 1–3 g dried boldo leaves per 250 mL water, steeped 10 minutes; provides a mixture of all 17+ boldo alkaloids with boldine as the dominant fraction but at modest absolute doses.
- **Standardized Boldo Extract Capsules**: Dry leaf extracts standardized to 0.5–1% boldine are commercially available, typically dosed at 250–500 mg per capsule; no evidence-based human efficacy dose exists.
- **Isolated Boldine (Research Grade)**: Used in preclinical studies at 20–75 mg/kg in rodents (oral or IP); direct human equivalent doses are not established and cannot be reliably extrapolated given <20% oral bioavailability and 30-minute half-life.
- **Boldine HCl Salt**: Water-soluble hydrochloride salt form (pKa ~9.7–10.8) used in research formulations for improved aqueous solubility in acidic pH; preferred for parenteral or in vitro experimental applications.
- **Topical Dicetyl Boldine (Lumiskin™)**: Diacetylated boldine derivative used in cosmetic skincare at manufacturer-specified concentrations for skin-brightening; not an oral supplement and not interchangeable with boldine alkaloid.
- **Timing**: No clinical timing data exist; based on rodent kinetics (peak plasma at 15–30 min post-oral dose), divided dosing would theoretically be required to maintain tissue exposure given rapid clearance.
- **Standardization Note**: No internationally recognized standardization benchmark for boldine content in supplements has been established by regulatory bodies; product quality varies widely.

Synergy & Pairings

Boldine has been studied in the context of boldo whole-leaf extracts, where co-occurring flavonoids and tannins may enhance its antioxidant effects through additive radical-scavenging capacity and improved aqueous solubility of the alkaloid matrix, though no controlled synergy experiments isolating this interaction have been published. Its connexin hemichannel-blocking mechanism is conceptually complementary to other anti-neuroinflammatory agents such as omega-3 fatty acids (EPA/DHA) that modulate glial activation through separate lipid-signaling pathways, suggesting a theoretical combinatorial neuroprotective stack, though this pairing has not been tested in vivo. Pairing boldine with phospholipid-based delivery systems (e.g., lecithin or phosphatidylcholine emulsions) has been proposed as a formulation strategy to overcome its low oral bioavailability (<20%) by reducing hepatic first-pass extraction, analogous to phytosome technology applied to other lipophilic alkaloids, but clinical validation of this approach for boldine specifically is lacking.

Safety & Interactions

Boldine demonstrated no genotoxic activity in two formal assay systems: no chromosome aberrations in cultured human lymphocytes at concentrations up to 40 μg/mL, and no bone marrow chromosomal damage in mice receiving up to 900 mg/kg orally, suggesting a favorable mutagenic safety margin well above likely human exposure levels. No specific adverse effects, organ toxicity findings, or clinically significant drug interactions have been reported in the published preclinical or human observational literature for boldine as an isolated compound, though the absence of human trial data means that rare or idiosyncratic reactions cannot be excluded. Boldine's interactions with dopamine D2 receptors and nicotinic acetylcholine receptors raise theoretical pharmacodynamic interaction concerns with dopaminergic medications (antipsychotics, dopamine agonists for Parkinson's disease) and cholinergic agents (acetylcholinesterase inhibitors), warranting caution in those patient populations until human interaction studies are conducted. Boldo leaf preparations (distinct from isolated boldine) contain ascaridole, a potentially hepatotoxic volatile compound; this risk does not apply to purified boldine but underscores the importance of distinguishing the isolated alkaloid from crude plant preparations, particularly in pregnancy and lactation where no safety data exist and use is not recommended.